Song Ran Liu1,2,3, Bo Qiu1,2,3, Hong Yang1,4,3, Ying Liang1,5,3, Fang Wang1,6,3, Shi Liang Liu1,2,3, Zhao Lin Chen1,2,3, Li Zhang1,5,3, Meng Zhong Liu1,2,3, Si Yu Wang1,4,3, Lan Feng Lin1,2,3, Hui Liu7,8,9. 1. State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China. 2. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China. 3. Guangdong Association Study of Thoracic Oncology, Guangzhou, People's Republic of China. 4. Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. 5. Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. 6. Molecular Diagnosis, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. 7. State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China. liuhui@sysucc.org.cn. 8. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China. liuhui@sysucc.org.cn. 9. Guangdong Association Study of Thoracic Oncology, Guangzhou, People's Republic of China. liuhui@sysucc.org.cn.
Abstract
BACKGROUND: This study aimed to investigate the association of epidermal growth factor receptor (EGFR) mutation status with treatment outcome for patients with stage 3 non-small cell lung cancer (NSCLC) who had undergone a complete (R0) resection. METHODS: The study identified 3445 NSCLC patients tested for EGFR mutations between September 2001 and December 2011 at the Sun Yat-Sen University Cancer Center. Of these patients, 224 were stage 3 patients who had undergone R0 resections. RESULTS: These 224 R0-resected, pathologic stage 3A and 3B patients included 150 patients with wild-type EGFR and 74 patients with EGFR mutations. During a median follow-up period of 42 months (range, 4-133 months), pathologic stage was shown to be the only prognostic factor. The 3-year overall survival (OS) rates did not differ significantly from the OS rates for the wild-type and mutant EGFR groups (62.0 vs 67.2 %; p = 0.789). Multivariate analyses indicated that the patients in the mutant EGFR group with EGFR exon 19 mutations had a better OS rate (73.0 vs 61.1 %; p = 0.026). CONCLUSIONS: Cancer stage remained the significant prognostic factor in R0-resected stage 3 NSCLC patients. The presence of an EGFR mutation is more likely to be a predictive marker for the response to treatment with tyrosine kinase inhibitors. In the EGFR mutant group, the patients with an exon 19 mutation had better 3-year OS rates. These findings might be considered in future study designs.
BACKGROUND: This study aimed to investigate the association of epidermal growth factor receptor (EGFR) mutation status with treatment outcome for patients with stage 3 non-small cell lung cancer (NSCLC) who had undergone a complete (R0) resection. METHODS: The study identified 3445 NSCLCpatients tested for EGFR mutations between September 2001 and December 2011 at the Sun Yat-Sen University Cancer Center. Of these patients, 224 were stage 3 patients who had undergone R0 resections. RESULTS: These 224 R0-resected, pathologic stage 3A and 3B patients included 150 patients with wild-type EGFR and 74 patients with EGFR mutations. During a median follow-up period of 42 months (range, 4-133 months), pathologic stage was shown to be the only prognostic factor. The 3-year overall survival (OS) rates did not differ significantly from the OS rates for the wild-type and mutant EGFR groups (62.0 vs 67.2 %; p = 0.789). Multivariate analyses indicated that the patients in the mutant EGFR group with EGFR exon 19 mutations had a better OS rate (73.0 vs 61.1 %; p = 0.026). CONCLUSIONS: Cancer stage remained the significant prognostic factor in R0-resected stage 3 NSCLCpatients. The presence of an EGFR mutation is more likely to be a predictive marker for the response to treatment with tyrosine kinase inhibitors. In the EGFR mutant group, the patients with an exon 19 mutation had better 3-year OS rates. These findings might be considered in future study designs.
Authors: Li Ma; Bo Qiu; Jun Zhang; Qi-Wen Li; Bin Wang; Xu-Hui Zhang; Meng-Yun Qiang; Zhao-Lin Chen; Su-Ping Guo; Hui Liu Journal: Chin J Cancer Date: 2017-12-11
Authors: Helen Pasternack; Christiane Kuempers; Mario Deng; Iris Watermann; Till Olchers; Mark Kuehnel; Danny Jonigk; Christian Kugler; Florian Stellmacher; Torsten Goldmann; Jutta Kirfel; Ole Ammerpohl; Sven Perner; Martin Reck Journal: Sci Rep Date: 2021-05-05 Impact factor: 4.379